Generic applications in Europe to fall as patent abyss recedes
This article was originally published in Scrip
Generic application filings in Europe are expected to plateau this year, even though the overall number of EMA marketing applications in 2012 is predicated to stay stable. The generics plateau follows a peak of generics filings in 2010 and 2011 as multiple innovator drugs teeter by the patent cliff.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.